Topic
Testosterone for women
Testosterone for women: why symptoms and blood levels do not diagnose “low T,” where evidence supports therapy, and how careful evaluation and monitoring work.
Start here
Symptoms, levels & HSDD
- Testosterone and Heart Risk in Women: Lipids and LimitsTestosterone heart risk in women should be framed as short-term reassurance with important limits, not evidence of long-term cardiovascular safety. A 2019 meta-analysis of 36 randomized trials with 8,480 participants found sexual function benefits in postmenopausal women and no increase in serious adverse events, but the trials were not designed to settle heart attacks, strokes, lifelong exposure, or high-risk cardiometabolic subgroups. The same review found oral testosterone worsened lipid measures compared with non-oral routes. Current guidance keeps the indication narrow: postmenopausal hypoactive sexual desire disorder after assessment, physiologic female-range exposure, baseline and follow-up testosterone monitoring, and lipid/liver review when relevant. [1]
- Testosterone Monitoring for Women After MenopauseTestosterone monitoring for women after menopause is mainly about keeping off-label hypoactive sexual desire disorder treatment inside a physiologic female exposure range. Global Consensus keeps the indication narrow, and the International Society for the Study of Women's Sexual Health says total testosterone is for baseline and safety monitoring, not diagnosis. [1] [2] It recommends baseline total testosterone, sex hormone-binding globulin, liver function, and fasting lipids, with early and ongoing testosterone rechecks. [2] The goal is benefit without supraphysiologic levels, androgenic side effects, lipid/liver problems, or no-benefit exposure beyond 6 months.
- Testosterone Pellets for Women After Menopause: Are They Safe?Testosterone pellets should not be treated as the default testosterone route for women after menopause. The global consensus statement says the only evidence-based indication for testosterone in women is postmenopausal women diagnosed with hypoactive sexual desire disorder. International Society for the Study of Women's Sexual Health guidance favors dosing that keeps levels in the physiologic premenopausal female range and says compounded testosterone, pellets, intramuscular injections, and oral formulations are not recommended. A clinician should diagnose hypoactive sexual desire disorder, review alternatives, check baseline testosterone and sex hormone-binding globulin, and monitor for acne, hair growth, voice change, and supraphysiologic levels. [1]
- Testosterone Side Effects in Women After MenopauseTestosterone side effects in women should be treated as dosing and monitoring signals, not cosmetic footnotes. The evidence-supported indication is narrow: postmenopausal hypoactive sexual desire disorder after biopsychosocial assessment. In a 2019 systematic review and meta-analysis of 36 randomized trials with 8,480 participants, testosterone improved sexual-function outcomes in postmenopausal women but increased androgenic effects such as acne and hair growth; oral testosterone also worsened lipid measures compared with non-oral routes. Monitoring should check baseline total testosterone, avoid supraphysiologic exposure, reassess benefit, and act on acne, unwanted facial hair, scalp hair changes, voice change, clitoral symptoms, mood changes, lipid issues, and product-transfer risk. [1]